Suppr超能文献

相似文献

1
Choice of Study Populations for Vaccines.
J Infect Dis. 2020 Mar 5;221(Suppl 1):S128-S134. doi: 10.1093/infdis/jiz537.
2
Scientific and Regulatory Considerations for Efficacy Studies of Cytomegalovirus Vaccines.
J Infect Dis. 2020 Mar 5;221(Suppl 1):S103-S108. doi: 10.1093/infdis/jiz523.
3
Vaccination against the human cytomegalovirus.
Vaccine. 2019 Nov 28;37(50):7437-7442. doi: 10.1016/j.vaccine.2018.02.089. Epub 2018 Apr 3.
4
The Status of Vaccine Development Against the Human Cytomegalovirus.
J Infect Dis. 2020 Mar 5;221(Suppl 1):S113-S122. doi: 10.1093/infdis/jiz447.
5
Criteria to define interruption of transmission of human cytomegalovirus from organ donor to recipient.
Rev Med Virol. 2018 Jan;28(1). doi: 10.1002/rmv.1958. Epub 2017 Nov 17.
6
Preventing Infection by Human Cytomegalovirus.
J Infect Dis. 2020 Mar 5;221(Suppl 1):S123-S127. doi: 10.1093/infdis/jiz448.
7
Review of Mathematical Models of Vaccination for Preventing Congenital Cytomegalovirus Infection.
J Infect Dis. 2020 Mar 5;221(Suppl 1):S86-S93. doi: 10.1093/infdis/jiz402.
8
Priorities for CMV vaccine development.
Vaccine. 2013 Dec 17;32(1):4-10. doi: 10.1016/j.vaccine.2013.09.042. Epub 2013 Oct 13.
9
Development of cytomegalovirus vaccines: prospects for prevention of congenital CMV infection.
Semin Pediatr Infect Dis. 2002 Jul;13(3):196-204. doi: 10.1053/spid.2002.125863.
10
Immunoprophylaxis against cytomegalovirus disease.
Scand J Infect Dis Suppl. 1995;99:105-9.

引用本文的文献

1
Seroprevalence of Cytomegalovirus and Associated Factors Among Preconception Women: A Cross-Sectional Nationwide Study in China.
Front Public Health. 2021 Aug 25;9:631411. doi: 10.3389/fpubh.2021.631411. eCollection 2021.
2
Pathogenesis of human cytomegalovirus in the immunocompromised host.
Nat Rev Microbiol. 2021 Dec;19(12):759-773. doi: 10.1038/s41579-021-00582-z. Epub 2021 Jun 24.

本文引用的文献

2
Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees.
J Virol. 2019 Feb 19;93(5). doi: 10.1128/JVI.01695-18. Print 2019 Mar 1.
4
HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.
Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6267-6272. doi: 10.1073/pnas.1800177115. Epub 2018 Apr 30.
5
Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.
Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6273-6278. doi: 10.1073/pnas.1800224115. Epub 2018 Apr 23.
7
8
Criteria to define interruption of transmission of human cytomegalovirus from organ donor to recipient.
Rev Med Virol. 2018 Jan;28(1). doi: 10.1002/rmv.1958. Epub 2017 Nov 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验